Over 1,000 Chemotherapy Protocols And Counting
New chemotherapy protocols are added weekly. All protocols are reviewed by Medical Oncologists and Hematologists.
New Indication: Pirtobrutinib for Untreated CLL without del(17p)
Pirtobrutinib showed superior progression-free survival compared to bendamustine plus rituximab with a hazard ratio of 0.199. It was well tolerated with significantly fewer adverse
New Protocol: Neoadjuvant Low-dose Pembrolizumab for Triple-Negative Breast Cancer
The PLANeT trial demonstrated that the addition of low-dose pembrolizumab (50 mg every 6 weeks) to standard chemotherapy significantly increased pathological complete response rate
New Reference: Adjuvant Nivolumab for Muscle-Invasive Bladder Cancer
The study found that adjuvant nivolumab significantly improved disease-free survival compared to placebo in patients with high-risk muscle-invasive urothelial carcinoma. The analys
New Protocol: Adjuvant Nivolumab with CISplatin Concurrently with Radiotherapy for Head and Neck Cancer
Adding nivolumab to cisplatin and radiotherapy significantly improved disease-free survival for high-risk resected LA-SCCHN. Nivolumab reduced locoregional relapses with a moderate
New Reference: FOLFOXIRI with Panitumumab for 1st Line Metastatic RAS/RAF WT Colorectal Cancer
The phase III TRIPLETE study shows that upfront mFOLFOXIRI plus panitumumab improved overall survival in patients with metastatic colorectal cancer compared to mFOLFOX plus panitum
New Reference: Erdafitinib for Cisplatin-Ineligible FGFR-Altered Metastatic Urothelial Carcinoma
Erdafitinib alone and in combination with cetrelimab demonstrated significant antitumor activity among cisplatin-ineligible patients with metastatic FGFR-altered urothelial carcino
New Reference: Datopotamab for HR-Positive HER2-Negative Metastatic Breast Cancer
Datopotamab deruxtecan showed a significant improvement in progression-free survival compared to investigator's choice chemotherapy. Overall survival did not show statistical signi
New Reference: Carboplatin with EC->T for Early-Stage Triple-Negative Breast Cancer
In this phase III trial, adding carboplatin to standard epirubicin, cyclophosphamide, and taxane regimen improved disease-free, distant disease-free, and overall survival in patien
New Protocol: Cabozantinib + Temozolomide for Leiomyosarcoma
Cabozantinib and temozolomide combination demonstrated promising clinical benefit in patients with unresectable or metastatic leiomyosarcoma. The treatment showed manageable advers
